Abstract
Nesfatin-1, derived from the nucleobindin-2 gene product, is expressed in neurons located in brain centers known to be important in the central regulation of both cardiovascular function and fluid and electrolyte homeostasis. In fact the peptide colocalizes in those neurons with an impressive list of neuropeptides and neurotransmitters known to be important in the regulation of thirst, appetite and central autonomic control. We and others have demonstrated potent sympatho-stimulatory actions of nesfatin-1 in brain and the potential physiologic relevance of those effects. In addition, although nesfatin-1 was originally described as a peptide with potent anorexigenic actions in brain, effects corroborated by several groups, it is possible that the anorexigenic actions of nesfatin-1 are secondary to a primary action to reduce thirst. Progress in unraveling the importance of endogenous nesfatin-1 in cardiovascular function, or fluid and electrolyte homeostasis, has been limited due to the to date unavailability of nesfatin-1 antagonists and the fact that the receptor for nesfatin-1 remains unidentified.
Keywords: Arterial pressure, sympathetic nervous system, hypothalamus, medulla, thirst, appetite.
Current Pharmaceutical Design
Title:Cardiovascular and Antidipsogenic Effects of Nesfatin-1
Volume: 19 Issue: 39
Author(s): Gina L.C. Yosten and Willis K. Samson
Affiliation:
Keywords: Arterial pressure, sympathetic nervous system, hypothalamus, medulla, thirst, appetite.
Abstract: Nesfatin-1, derived from the nucleobindin-2 gene product, is expressed in neurons located in brain centers known to be important in the central regulation of both cardiovascular function and fluid and electrolyte homeostasis. In fact the peptide colocalizes in those neurons with an impressive list of neuropeptides and neurotransmitters known to be important in the regulation of thirst, appetite and central autonomic control. We and others have demonstrated potent sympatho-stimulatory actions of nesfatin-1 in brain and the potential physiologic relevance of those effects. In addition, although nesfatin-1 was originally described as a peptide with potent anorexigenic actions in brain, effects corroborated by several groups, it is possible that the anorexigenic actions of nesfatin-1 are secondary to a primary action to reduce thirst. Progress in unraveling the importance of endogenous nesfatin-1 in cardiovascular function, or fluid and electrolyte homeostasis, has been limited due to the to date unavailability of nesfatin-1 antagonists and the fact that the receptor for nesfatin-1 remains unidentified.
Export Options
About this article
Cite this article as:
Yosten L.C. Gina and Samson K. Willis, Cardiovascular and Antidipsogenic Effects of Nesfatin-1, Current Pharmaceutical Design 2013; 19 (39) . https://dx.doi.org/10.2174/138161281939131127142720
DOI https://dx.doi.org/10.2174/138161281939131127142720 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circulating and Vascular Bioactive Factors During Hypertension in Pregnancy
Current Bioactive Compounds Clinical Implications of Non-Invasive Measurement of Central Aortic Blood Pressure
Current Vascular Pharmacology Effects of Drugs, Phytoestrogens, Nutrients and Probiotics on Endothelial Dysfunction in the Estrogen-Deficient State
Current Pharmaceutical Design Socioeconomic Position and Type 2 Diabetes Mellitus in Europe 1999- 2009: a Panorama of Inequalities
Current Diabetes Reviews Common Therapeutic Strategies in the Management of Sexual Dysfunction and Cardiovascular Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Hypogonadotrophic Hypogonadism in Type 2 Diabetes, Obesity and the Metabolic Syndrome
Current Molecular Medicine Ischemic Neuronal Damage
Current Pharmaceutical Design Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery
Current Drug Therapy Overlap Syndrome of Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea: A Two-Faced Janus
Current Respiratory Medicine Reviews Graphical Abstracts:
Current Nutrition & Food Science Exercise and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Improving the Efficiency and Safety of Aspirin by Complexation with the Natural Polysaccharide Arabinogalactan
Current Drug Delivery Relation Between Obstructive Sleep Apnea Syndrome and Resistant Hypertension - The Tip of the Iceberg
Current Respiratory Medicine Reviews Traditional Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes Mellitus
Current Diabetes Reviews Metabolic Syndrome in HIV-patients in Antiretroviral Therapy
Current HIV Research Cardio-vascular Activity of Catestatin: Interlocking the Puzzle Pieces
Current Medicinal Chemistry MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets Interaction studies of Withania somnifera’s key metabolite Withaferin A with different receptors associated with cardiovascular disease
Current Computer-Aided Drug Design Nutrition Transition and Obesity Among Teenagers and Young Adults in South Asia
Current Diabetes Reviews